概述
-
货号
FHC25220
-
种属反应性
Human -
宿主
Mouse -
同种型
IgG2a, kappa -
克隆类型
Monoclonal -
偶联物
Unconjugated -
靶标
CD115, CSF-1 receptor, CSF1R, M-CSF-R, CSF-1-R, Proto-oncogene c-Fms, Macrophage colony-stimulating factor 1 receptor, CSF-1R, FMS -
浓度
1.3 mg/ml -
内毒素水平
Please contact with the lab for this information. -
纯度
>95% as determined by SDS-PAGE. -
纯化方式
Protein A/G purified from cell culture supernatant. -
Accession号
P07333 -
克隆号
RG7155
-
应用
FCM -
状态
Liquid -
保存溶液
0.01M PBS, pH 7.4. -
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
图片
参考文献
- Phase I study of RG7155, a novel anti-CSF1R antibody, in patients with advanced/metastatic solid tumors.
- Comprehensive biomarker program demonstrates proof of mechanism and modulation of the tumor microenvironment due to RG7155, a novel therapeutic antibody …
- Exploratory biomarker program in Phase I clinical development of RG7155, a novel humanized anti-CSF-1R Mab, targeting Tumor Associated Macrophages (TAMs).
- Phase 1 study of RG7155, a novel anti-CSF1R antibody, in patients with locally advanced pigmented villonodular synovitis (PVNS).
- Macrophage susceptibility to emactuzumab (RG7155) treatment
- Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy
- Targeting tumor-associated macrophages in cancer patients
- Clinical development of colony-stimulating factor 1 receptor (CSF1R) inhibitors
- CSF-1/CSF-1R targeting agents in clinical development for cancer therapy
- Targeting the depletion of M2 macrophages: implication in cancer immunotherapy
- Potential contribution of tumor-associated slan+ cells as anti-CSF-1R targets in human carcinoma
- CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 …
- CSF-1R inhibitor development: current clinical status
- Colony-Stimulating Factor 1 Receptor: A Novel Target for Cancer Immunotherapy
- Targeting macrophages: a novel avenue for cancer drug discovery
- First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors
- Update of early phase clinical trials in cancer immunotherapy
- Targeting of Suppressive Myeloid Cells via Small Molecule Immunomodulators
- Immunotherapy for Pancreatic Cancer
评价
